My Lords, although I agree with the comments made by the noble Lords, Lord Hunt of Kings Heath and Lord Clement-Jones, also affecting the manufacture and development of medicines in the United Kingdom now is our ability to conduct clinical trials, particularly phase 3 trials. We are good at starting phase 1 trials but by the time it comes to phase 3, not enough patients have been recruited and so the commercial trials come to an end. That means that we are not developing new medicines for cancers, cardiac disease and rare diseases. We need much more co-ordination from the Government, from the regulatory authorities for medicine and the ethics research authority, and from integrated care boards and trusts, so that the recruitment of patients continues at phase 3.